Mark E Saad sold $1.1M of AXSM
director at Axsome Therapeutics, Inc.. 9,127 shares at an average of $125.07, traded Sep 5, 2025, filed Sep 5, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.1M at market
- +10Share of holdings soldSold 48% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.9%, 3m +19.2%, 6m +29.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-113311, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 5, 2025 | MOption exercise Common Stock10b5-1 | +9,127 | $9.00 | $82k | 19,129 | Sep 5, 2025 |
| Sep 5, 2025 | SOpen-market sale Common Stock10b5-1 | -9,127 | $125.07 | $1.1M | 10,002 | Sep 5, 2025 |
| Sep 5, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,127 | $0.00 | $0 | 0 | Sep 5, 2025 |
Related signals
Other insiders at Axsome Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Axsome Therapeutics, Inc. | Mark L. Jacobson Chief Operating Officer | $2.1M 10,000 shares | -100% | |
| 21Weak | Axsome Therapeutics, Inc. | Roger Jeffs director | $142k 572 shares | -1% | |
| 6Weak | Axsome Therapeutics, Inc. | Mark Coleman director | $160k 643 shares | -2% | |
| 16Weak | Axsome Therapeutics, Inc. | Susan Mahony director | $145k 600 shares | -42% | |
| 37Weak | Axsome Therapeutics, Inc. | Nick Pizzie Chief Financial Officer | $7.9M 33,000 shares | -43% | |
| 50Moderate | Axsome Therapeutics, Inc. | Herriot Tabuteau Chief Executive Officer | $12M 49,670 shares | -87% | |
| 45Moderate | Axsome Therapeutics, Inc. | Mark Coleman director | $4.0M 17,537 shares | -37% | |
| 38Weak | Axsome Therapeutics, Inc. | Mark L. Jacobson Chief Operating Officer | $1.1M 4,750 shares | -105% | |
| 33Weak | Axsome Therapeutics, Inc. | Ari Maizel Chief Commercial Officer | $1.4M 7,500 shares | -100% | |
| 38Weak | Axsome Therapeutics, Inc. | Mark L. Jacobson Chief Operating Officer | $5.7M 35,378 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.